Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes.
about
Home versus hospital intravenous antibiotic therapy for cystic fibrosisHome versus hospital intravenous antibiotic therapy for cystic fibrosisOral, inhaled, and intravenous antibiotic choice for treating pulmonary exacerbations in cystic fibrosis.Pseudomonas aeruginosa infection in patients with cystic fibrosis: scientific evidence regarding clinical impact, diagnosis, and treatmentAssessing time to pulmonary function benefit following antibiotic treatment of acute cystic fibrosis exacerbationsState of progress in treating cystic fibrosis respiratory disease.Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbationsIron homeostasis during cystic fibrosis pulmonary exacerbationShort-term and long-term response to pulmonary exacerbation treatment in cystic fibrosis.One Center's Guide to Outpatient Management of Pediatric Cystic Fibrosis Acute Pulmonary Exacerbation.Managing cystic fibrosis: strategies that increase life expectancy and improve quality of life.Update in cystic fibrosis 2010.Management of pulmonary exacerbations in cystic fibrosis: still an unmet medical need in clinical practice.Respiratory tract exacerbations revisited: ventilation, inflammation, perfusion, and structure (VIPS) monitoring to redefine treatment.Standardized Treatment of Pulmonary Exacerbations (STOP) study: Observations at the initiation of intravenous antibiotics for cystic fibrosis pulmonary exacerbations.Special considerations for the treatment of pulmonary exacerbations in children with cystic fibrosis.The use, appropriateness and outcomes of outpatient parenteral antimicrobial therapy.Probability of IV antibiotic retreatment within thirty days is associated with duration and location of IV antibiotic treatment for pulmonary exacerbation in cystic fibrosis.Relationship of Antibiotic Treatment to Recovery after Acute FEV1 Decline in Children with Cystic Fibrosis.Constrictive Bronchiolitis in Cystic Fibrosis Adolescents with Refractory Pulmonary Decline.Is there a role for antimicrobial stewardship in cystic fibrosis?Physical activity in adults with cystic fibrosis receiving intravenous antibiotics in hospital and in the community.Brazilian guidelines for the diagnosis and treatment of cystic fibrosis.Study design considerations for the Standardized Treatment of Pulmonary Exacerbations 2 (STOP2): A trial to compare intravenous antibiotic treatment durations in CF.Daily spirometry in an acute exacerbation of adult cystic fibrosis patients.Recent advances in the understanding and management of cystic fibrosis pulmonary exacerbations.
P2860
Q24187116-45B8E350-798F-418D-A847-CED771355C0BQ24201353-1A2D4FDD-0997-4D86-BE70-900ACFFD2F7EQ33725822-98B386F8-CE2F-4248-B8E0-CE3FF208D17AQ33824149-62286A51-06C2-4132-94AE-9DDCF5CAC380Q34221582-E03CA22F-3CF9-4093-B527-31FF0F696F06Q34375926-166F1839-5F8C-49C4-A33F-4960F5C02D6AQ34706914-FDAC6E7E-C229-4A29-BCDF-B3AC0A035C44Q36165392-ECB571E2-E63C-430A-9F74-26DFE93E001AQ36652904-DFEDBE06-D792-49ED-85DA-B2BD0D2960C5Q37094805-422B02D8-EE95-4FFC-8530-9B34EDC2CCFDQ37844338-2CE4BA1D-E5FD-413D-B870-6774051912F2Q37892766-DA306990-C2D3-4F6F-BBA0-3314BBD0FFF5Q38360133-4728273F-0B5E-46BC-A83D-EC53951E860FQ38579964-DAC62369-B6B4-4832-98A1-03C697F44C1AQ38688865-49DA5CD1-A9FA-4660-AAE7-AC59618D20FEQ38975705-860BB87E-05D9-4AE6-8A1A-7F44C593E319Q39776778-915DAE1A-D654-47F3-8BD2-DFC250DFF4E5Q39800405-FA17AC08-5F5B-4141-A027-C12DE5B12A7FQ40282373-9B505D0F-EE77-4A02-A727-E897B2F13AB5Q40560942-571F54AA-C522-4816-9D29-EE83DB46974CQ42202818-D4FBF4CC-5459-41C9-B831-E66969DD5596Q43171411-B474BF0A-1A9E-449B-975A-173DE33B122CQ43538692-2B830424-7A32-456F-A5D6-CF6ADCDCC195Q47422154-FD6260FE-4876-45A8-B2E7-96AE7D1D0B08Q49571544-97AD614B-D8E3-4BA6-B4A5-E6837E726585Q55437809-721D4FEE-924D-4F7B-AB97-8D4C730ACD1C
P2860
Location and duration of treatment of cystic fibrosis respiratory exacerbations do not affect outcomes.
description
2010 nî lūn-bûn
@nan
2010 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
name
Location and duration of treat ...... ations do not affect outcomes.
@ast
Location and duration of treat ...... ations do not affect outcomes.
@en
Location and duration of treat ...... ations do not affect outcomes.
@nl
type
label
Location and duration of treat ...... ations do not affect outcomes.
@ast
Location and duration of treat ...... ations do not affect outcomes.
@en
Location and duration of treat ...... ations do not affect outcomes.
@nl
prefLabel
Location and duration of treat ...... ations do not affect outcomes.
@ast
Location and duration of treat ...... ations do not affect outcomes.
@en
Location and duration of treat ...... ations do not affect outcomes.
@nl
P2093
P2860
P1476
Location and duration of treat ...... ations do not affect outcomes.
@en
P2093
Deanna M Green
Garry R Cutting
J Michael Collaco
Kathleen M Naughton
Peter J Mogayzel
P2860
P304
P356
10.1164/RCCM.201001-0057OC
P407
P577
2010-06-25T00:00:00Z